Protocol Ledger

NCT04233346 · Phase II · COMPLETED

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Interventional Phase II clinical trial protocol NCT04233346 sponsored by Otsuka Beijing Research Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-09 Enrollment: 93 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04233346
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)93 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04233346
Protocol FieldVerified Registry Value
NCT IdentifierNCT04233346
Consolidated Lead SponsorOtsuka Beijing Research Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment93 participants (ACTUAL)
Registered Start Date2020-07-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI